Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioheart Pursues OrCel Cardiac Regeneration; Ortec Chases Ulcer Claims

This article was originally published in The Gray Sheet

Executive Summary

Bioheart, Inc.'s Myocell may provide Ortec entry into the cardiovascular regeneration market, under a deal covering the cell transplantation product in combination with Ortec's OrCel collagen sponge and vascular endothelial growth factor technologies
Advertisement

Related Content

Ortec OrCel
Ortec OrCel
Medtronic Vascular Sales Remain Steady Despite Cypher Competition
Medtronic Vascular Sales Remain Steady Despite Cypher Competition
ATS Gives Smith & Nephew Second Skin; Wound Treatment Portfolio Elevated
ATS Gives Smith & Nephew Second Skin; Wound Treatment Portfolio Elevated
ATS/Medtronic Expect Epicardial Angiogenesis Device Trials By 2003
Ortec Claiming OrCel Superiority Over Standard Burn Donor Site Treatments
Ortec Claiming OrCel Superiority Over Standard Burn Donor Site Treatments
Ortec CCS Venous Leg Ulcer PMA Due 2002; Panel Will Review Burn Indication
Advertisement
UsernamePublicRestriction

Register

MT016954

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel